Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efanesoctocog alfa (BIVV001) pharmacokinetics in severe hemophilia A
NCT05042440Phase 1Completed
- Sponsor
- Sanofi
- Start
- Aug 2021
- Primary completion
- Nov 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of efanesoctocog alfa in hemophilia A, sponsored by Sanofi. Primary endpoints: Half-life of BIVV001 at 28 days, Half-life of Standard Half-Life rFVIII at 72 hours and 1 more. Started Aug 2021; status: completed.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT05042440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05042440.